Psoriatic arthritis drug apremilast tracked for two years in Real-World study

NCT ID NCT03106051

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 526 adults with active psoriatic arthritis who were already prescribed apremilast (Otezla) by their doctors. Researchers observed them for up to 100 weeks to see how well the drug controlled their symptoms in everyday practice. The goal was to gather long-term data on effectiveness and safety outside of a controlled trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apremilast (Otezla)
What this could lead to: If successful, this study could confirm that apremilast is a safe and effective long-term option for managing psoriatic arthritis symptoms in everyday practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It does not test a new treatment, only documents existing use, and long-term benefits or risks remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS, PSORIATIC

Contacts and locations

Locations

Klinikum Stephansplatz

Hamburg, 20354, Germany
Rheumatology at Struenseehaus

Altona, Free and Hanseatic City of Hamburg, 22767, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.